Mourad Tiab

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · New England Journal of Medicine · 2014 · 786 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Thierry Façon, Shaji Kumar, Torben Plesner et al. · The Lancet Oncology · 2021 · 363 citations · Full text

Medicine, Oncology, Pharmacotherapy +13